Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 273-287

  Shevtsov, Maxim A ^a,b   Nikolaev, Boris P ^c   Yakovleva, Ludmila Y ^c   Marchenko, Yaroslav Y ^c   Dobrodumov, Anatolii V ^d   Mikhrina, Anastasiya L ^e   Martynova, Marina G ^a   Bystrova, Olga A ^a   Yakovenko, Igor V ^b   Ischenko, Alexander M ^c  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^c Institute for Highly Pure Biopreparations   (Russian Federation)

^d INSTITUTE OF MACROMOLECULAR COMPOUNDS   (Russian Federation)

^e SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

Brain tumor; C6 glioma; EGFR; Epidermal growth factor; Magnetic nanoparticles; MRI contrast agent; SPION

Indexed keywords

NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE RECOMBINANT EPIDERMAL GROWTH FACTOR CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PENETRATION; DRUG TARGETING; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MALE; NANOPHARMACEUTICS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY;

BRAIN TUMOR; C6 GLIOMA; EGFR; EPIDERMAL GROWTH FACTOR; MAGNETIC NANOPARTICLES; MRI CONTRAST AGENT; SPION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DEXTRANS; EPIDERMAL GROWTH FACTOR; GLIOMA; MAGNETITE NANOPARTICLES; NANOCAPSULES; RATS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84891753109     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55118     Document Type: Article

References (40)

1. Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol. 2012;5(2): 173-186
2. Hadjipanayis CG, Machaidze R, Kaluzova M, EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70(15):6303-6312
3. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317-324
4. Tong S, Hou S, Zheng Z, Zhou J, Bao G. Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett. 2010;10(11):4607-4613
5. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21): 2683-2710
6. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6(3):217-223; discussion 23-24
7. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2): 124-134
8. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16(6):748-754
9. Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 2001;162 Suppl:S17-S21
10. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001;61(14):5349-5354
11. Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 2008;19(2):99-113
12. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005;56(1):155-162; discussion 162
13. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773-2779
14. Kohno M, Horibe T, Haramoto M, et al. A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer. 2011;47(5):773-783
15. Kang CS, Zhang ZY, Jia ZF, et al. Suppression of EGFR expression by antisense or small interference RNA inhibits U251glioma cell growth in vitro and in vivo. Cancer Gene Ther. 2006;13(5):530-538
16. Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed). 2011;16: 1962-1972
17. Kullberg EB, Nestor M, Gedda L. Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm Res. 2003;20(2):229-236
18. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFRand EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63(12):3154-3161
19. Kim IY, Kang YS, Lee DS, et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release. 2009;140(1):55-60
20. Sandoval MA, Sloat BR, Lansakara-P DS, et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J Control Release. 2012;157(2):287-296
21. Nikolaev BP, Marchenko YY, Yakovleva LY, et al. Magnetic epidermal growth factor conjugate for targeted delivery to grafted tumor in mouse model. IEEE Transactions on Magnetics. 2013;49(1):429-435
22. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Transactions on Magnetics. 1981;17(2):1247-1248
23. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44(10):842-852
24. Marchenko YY, Shishkin AN, Yakovleva LY, Nikolaev BP. The mag-netic relaxation platform for biosensing cancer markers: the relaxivity of magnetic nanoparticles conjugated with epidermal growth factor under influence of its antibody. In: Program and abstracts of the Nuclear Magnetic Resonance in Condensed Matter 9th Meeting: NMR in Heterogeneous Systems; July 9-13, 2012; St Petersburg, Russia 104
25. Sirol M, Itskovich VV, Mani V, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation. 2004;109(23):2890-2896
26. Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release. 2007;122(3):315-323
27. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24): 6317-6324
28. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-496
29. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60(23):6641-6648
30. Lübbe AS, Bergemann C, Huhnt W, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996; 56(20):4694-4701
31. Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56(20):4686-4693
32. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002;39(2):162-173
33. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 2003;278(6): 4135-4144
34. Veiseh O, Gunn JW, Kievit FM, et al. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small. 2009;5(2):256-264
35. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanopar-ticles for MR imaging and drug delivery. Small. 2006;2(6):785-792
36. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified super-paramagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 2005;21(19):8858-8864
37. Lee KJ, An JH, Chun JR, et al. In vitro analysis of the anti-cancer activity of mitoxantrone loaded on magnetic nanoparticles. J Biomed Nanotechnol. 2013;9(6):1071-1075
38. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013;50(2):191-197
39. Viota JL, Carazo A, Munoz-Gamez JA, et al. Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gem-citabine to tumor cells. Physicochemical in vitro evaluation. Mater Sci Eng C Mater Biol Appl. 2013;33(3):1183-1192
40. Erten A, Wrasidlo W, Scadeng M, et al. Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine. 2010;6(6):797-807